Genelink

Genelink FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Genelink (GNLKQ) as of Oct 9, 2026 is 86.03 %.

FCF Conversion

86.03 %

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Genelink is 2012 86.03 % . FCF Conversion Rate (FCF/EBITDA) of Genelink was 2011 - . It decreases by % lower compared to the previous year.

The Genelink FCF Conversion history

The Genelink FCF Conversion history
YEARFCF ConversionYoY
86.03 %—
Access this data via the Eulerpool API

Genelink Stock analysis

What does Genelink do? Genelink Inc is a company specializing in the development and marketing of dietary supplements and health products. It was founded in 1996 by Dr. Alan Darmitzel and is headquartered in Salt Lake City, Utah, USA. The company's business model is based on personalizing dietary supplements and health promotion products. Genelink uses DNA analysis to determine the specific needs of each customer and manufactures customized dietary supplements and health products based on these results. Genelink offers a wide range of health products tailored to the needs of each individual. The company has various divisions that offer products such as dietary supplements, skincare products, and weight management products. Genelink supplies a variety of dietary supplements tailored to the needs of each individual customer. The supplements contain ingredients tailored to each customer's genetic profile. For example, a customer at high risk for heart disease may be offered a dietary supplement with ingredients that can reduce the risk of heart disease. Genelink also offers a range of skincare products tailored to the individual needs of each customer. The skincare products contain ingredients tailored to each customer's specific needs, such as skin type and age. The company also offers specialized weight management products tailored to the individual needs of each customer. The products contain ingredients that facilitate weight management and can reduce the risk of weight gain. In summary, Genelink Inc is a company that offers personalized health solutions. Based on the results of DNA analysis, the company manufactures customized dietary supplements, skincare products, and weight management products. Genelink's products and services are designed to meet the individual needs of each customer and provide a personalized approach to health promotion. Genelink is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genelink stock

FCF Conversion Rate (FCF/EBITDA) of Genelink is 86.03 % in 2012.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Genelink since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Genelink with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Genelink

All Key Metrics — Genelink